|
|
|
|
Anti-N-methyl-D-aspartate Receptor Encephalitis
_ Anti-N-methyl-D-aspartate Receptor Encephalitis.
|
|
|
Anti-N-methyl-D-aspartate Receptor Encephalitis
In order to use Medscape, your browser must be set to accept cookies delivered by the Medscape site.To find out how to adjust your browser settings to accept cookies, please click here. Medscape uses cookies to customize the site based on the information...
|
|
|
Japanese Encephalitis Vaccines -- Recommendations of the Advisory Committee on Immunization Practices (ACIP)
Prepared by Marc Fischer, MD, Nicole Lindsey, MS, J.Erin Staples, MD, PhD, Susan Hills, MBBS Division of Vector-Borne Infectious Diseases, National Center for Emerging and Zoonotic Infectious Diseases (proposed), CDC This report originated in the National...
|
|
|
What Is Japanese Encephalitis? What Causes Japanese Encephalitis?
Japanese encephalitis (JE), or Japanese B encephalitis to distinguish it from von Economo's A encephalitis, is a viral disease caused by a type of virus called a flavivirus.It is spread through the bite of an infected mosquito. Usually, the illness is mild...
|
|
|
Encephalitis Animal Studies: Scientists at University Medical Center discuss research in encephalitis animal studies
Today's Medical & Research News Scientists at University Medical Center discuss research in March 5th, 2010 Printer-Friendly Version City:Groningen Country:Netherlands Encephalitis HSV-1 Herpes Virus Herpesvirus Mental Health Neuroinflammation...
|
|
|
Joint Committee on Vaccination and Immunization (JCVI) in the UK broadens Japanese Encephalitis immunization r
First country specific recommendation in Europe Key to foster product awareness for Intercells vaccine to prevent Japanese Encephalitis Vienna (Austria), March 4, 2010 Intercell AG (VSE: ICLL) today announced that Joint Committee on Vaccination and...
|
|
|
Intercell Announces Q4 and Preliminary Full Year 2009 Financial Results
VIENNA, March 2 /PRNewswire-FirstCall/ -- Today, the biotech-vaccine company Intercell AG (Pink Sheets: INRLY) (VSE: ICLL) announced its financial results for Q4 and the preliminary results for the full financial year 2009, and presented an update on the...
|
|
|
Intercell Announces Q4 and Preliminary Full Year 2009 Financial Results
VIENNA, March 2 /PRNewswire-FirstCall/ -- Today, the biotech-vaccine company Intercell AG (Pink Sheets: INRLY) (VSE: ICLL) announced its financial results for Q4 and the preliminary results for the full financial year 2009, and presented an update on the...
|
|
|
Austrian Intercell reports higher-than-expected net loss for 2009, shares dip 8%
- Austrian biotechnology company Intercell AG (WBAG:ICLL) posted on Tuesday a net loss of EUR 18.4 million (USD 24.9m) for 2009, surprising analysts who had projected a loss of only EUR 13 million.A consensus forecast of experts from Raiffeisen Centrobank ...
|
|
|
Intercell Announces Q4 and Preliminary Full Year 2009 Financial Results
VIENNA, March 2 /PRNewswire-FirstCall/ -- Today, the biotech-vaccine company Intercell AG (Pink Sheets: INRLY) (VSE: ICLL) announced its financial results for Q4 and the preliminary results for the full financial year 2009, and presented an update on the...
|
|
|
Intercell Announces Q4 and Preliminary Full Year 2009 Financial Results
Today, the biotech-vaccine company Intercell AG (Pink Sheets: INRLY) (VSE: ICLL) announced its financial results for Q4 and the preliminary results for the full financial year 2009, and presented an update on the Company's development programs.Intercell's...
|
|
|
Intercell Announces Q4 and Preliminary Full Year 2009 Financial Results
Today, the biotech-vaccine company Intercell AG (Pink Sheets: INRLY) (VSE: ICLL) announced its financial results for Q4 and the preliminary results for the full financial year 2009, and presented an update on the Company's development programs.Intercell's...
|
|
|
Intercell Announces Q4 and Preliminary Full Year 2009 Financial Results
VIENNA, March 2 /PRNewswire-FirstCall/ -- Today, the biotech-vaccine company Intercell AG (Pink Sheets: INRLY) (VSE: ICLL) announced its financial results for Q4 and the preliminary results for the full financial year 2009, and presented an update on the...
|
|
|
Intercell Announces Q4 and Preliminary Full Year 2009 Financial Results
Today, the biotech-vaccine company Intercell AG (Pink Sheets: INRLY) (VSE: ICLL) announced its financial results for Q4 and the preliminary results for the full financial year 2009, and presented an update on the Company's development programs.Intercell's...
|
|
|
Intercell Announces Q4 and Preliminary Full Year 2009 Financial Results
Today, the biotech-vaccine company Intercell AG (Pink Sheets: INRLY) (VSE: ICLL) announced its financial results for Q4 and the preliminary results for the full financial year 2009, and presented an update on the Company's development programs.Intercell's...
|
|
|
Intercell Announces Q4 and Preliminary Full Year 2009 Financial Results
Today, the biotech-vaccine company Intercell AG (Pink Sheets: INRLY) (VSE: ICLL) announced its financial results for Q4 and the preliminary results for the full financial year 2009, and presented an update on the Company's development programs.Intercell's...
|
|
|
Intercell Announces Q4 and Preliminary Full Year 2009 Financial Results
Today, the biotech-vaccine company Intercell AG (Pink Sheets: INRLY) (VSE: ICLL) announced its financial results for Q4 and the preliminary results for the full financial year 2009, and presented an update on the Company's development programs.Intercell's...
|
|
|
Intercell Announces Q4 and Preliminary Full Year 2009 Financial Results
Today, the biotech-vaccine company Intercell AG (Pink Sheets: INRLY) (VSE: ICLL) announced its financial results for Q4 and the preliminary results for the full financial year 2009, and presented an update on the Company's development programs.Intercell's...
|
|
|
Intercell Announces Q4 and Preliminary Full Year 2009 Financial Results
Today, the biotech-vaccine company Intercell AG (Pink Sheets: INRLY) (VSE: ICLL) announced its financial results for Q4 and the preliminary results for the full financial year 2009, and presented an update on the Company's development programs.Intercell's...
|
|
|
Intercell Announces Q4 and Preliminary Full Year 2009 Financial Results
Today, the biotech-vaccine company Intercell AG (Pink Sheets: INRLY) (VSE: ICLL) announced its financial results for Q4 and the preliminary results for the full financial year 2009, and presented an update on the Company's development programs.Intercell's...
|
|
|
Intercell AG's revenues for full year 2009 increase 10.6%
Today, the biotech-vaccine company Intercell AG (Pink Sheets: INRLY) (VSE: ICLL) announced its financial results for Q4 and the preliminary results for the full financial year 2009, and presented an update on the Company's development programs.Intercell's...
|
|
|
Intercell Announces Q4 and Preliminary Full Year 2009 Financial Results
Today, the biotech-vaccine company Intercell AG (Pink Sheets: INRLY) (VSE: ICLL) announced its financial results for Q4 and the preliminary results for the full financial year 2009, and presented an update on the Company's development programs.Intercell's...
|
|
|
Intercell Announces Q4 and Preliminary Full Year 2009 Financial Results
Today, the biotech-vaccine company Intercell AG (Pink Sheets: INRLY) (VSE: ICLL) announced its financial results for Q4 and the preliminary results for the full financial year 2009, and presented an update on the Company's development programs.Intercell's...
|
|
|
Intercell Announces Q4 and Preliminary Full Year 2009 Financial Results
Today, the biotech-vaccine company Intercell AG (Pink Sheets: INRLY) (VSE: ICLL) announced its financial results for Q4 and the preliminary results for the full financial year 2009, and presented an update on the Company's development programs.Intercell's...
|
|
|
Intercell Announces Q4 and Preliminary Full Year 2009 Financial Results
Today, the biotech-vaccine company Intercell AG (Pink Sheets: INRLY) (VSE: ICLL) announced its financial results for Q4 and the preliminary results for the full financial year 2009, and presented an update on the Company's development programs.Intercell's...
|